Combined schedule of fludarabine and alemtuzumab followed by maintenance with low-dose alemtuzumab is effective for patients with progressive B-cell chronic lymphocytic leukemia.

被引：0
|
作者：
Kowal, M
Nowak, W
Nowaczynska, A
Dmoszynska, A
Skotnicki, AB
机构：
[1] Jagiellonian Univ, Fac Med, Dept Haematol, Krakow, Poland
[2] Med Univ Lublin, Dept Haematooncol & Bone Marrow Transplantat, Lublin, Poland
来源：
BLOOD | 2005年 / 106卷 / 11期
关键词：
D O I：
暂无
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
5048
引用
收藏
页码：343B / 344B
页数：2
相关论文
共 50 条
  • [1] Activity and safety of combined fludarabine and alemtuzumab followed by low-dose alemtuzumab maintenance therapy in patients with B-CLL.
    Kowal, Malgorzata
    Dmoszynska, Anna
    BLOOD, 2006, 108 (11) : 337B - 337B
  • [2] The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia
    Tarnani, M.
    D'Arena, G.
    Efremov, D. G.
    Marietti, S.
    Sica, S.
    Leone, G.
    Laurenti, L.
    LEUKEMIA, 2010, 24 (04) : 890 - 891
  • [3] The use of low-dose alemtuzumab in pretreated B-cell chronic lymphocytic leukemia
    M Tarnani
    G D'Arena
    D G Efremov
    S Marietti
    Sica S
    G Leone
    L Laurenti
    Leukemia, 2010, 24 : 890 - 891
  • [4] Alemtuzumab is effective in the treatment of patients with advanced, heavily pretreated B-cell chronic lymphocytic leukemia.
    Fiegl, M
    Hopfinger, G
    Jaeger, G
    Fridrik, M
    Zojer, N
    Walla, B
    Andel, J
    Schmid, FX
    Weisz, H
    Mayer, P
    Buchel, J
    Greil, R
    BLOOD, 2003, 102 (11) : 358B - 358B
  • [5] Low dose alemtuzumab in patients with fludarabine-refractory chronic lymphocytic leukemia
    Gritti, Giuseppe
    Reda, Gianluigi
    Maura, Francesco
    Piciocchi, Alfonso
    Baldini, Luca
    Molica, Stefano
    Neri, Antonino
    Cortelezzi, Agostino
    LEUKEMIA & LYMPHOMA, 2012, 53 (03) : 424 - 429
  • [6] Alemtuzumab in B-cell chronic lymphocytic leukemia
    Shapira, I
    Grossbard, ML
    CLINICAL LYMPHOMA, 2004, 4 (04): : 228 - 229
  • [7] Alemtuzumab for B-cell chronic lymphocytic leukemia
    Robak, Tadeusz
    EXPERT REVIEW OF ANTICANCER THERAPY, 2008, 8 (07) : 1033 - 1051
  • [8] Alemtuzumab in the treatment of fludarabine refractory B-cell chronic lymphocytic leukemia (CLL)
    Montillo, Marco
    Ricci, Francesca
    Miqueleiz, Sara
    Tedeschi, Alessandra
    Morra, Enrica
    BIOLOGICS-TARGETS & THERAPY, 2008, 2 (01): : 41 - 52
  • [9] Low-dose alemtuzumab as treatment of autoimmune hemolytic anemia in pretreated B-cell chronic lymphocytic leukemia
    Tarnani, M.
    Laurenti, L.
    Efremov, D. G.
    Fiorini, A.
    De, Matteis S.
    Chiusolo, P.
    De, Padua L.
    Innocenti, I.
    Sora, F.
    Sica, S.
    Leone, G.
    HAEMATOLOGICA-THE HEMATOLOGY JOURNAL, 2007, 92 : 115 - 116
  • [10] Pharmacokinetics of alemtuzumab in combination with fludarabine in patients with relapsed or refractory B-cell chronic lymphocytic leukemia
    Elter, Thomas
    Kilp, Julia
    Borchmann, Peter
    Schulz, Holger
    Hallek, Michael
    Engert, Andreas
    Haematologica-The Hematology Journal, 2009, 94 (01): : 150 - 152
12345